

Vikas Ostwal Dm

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2426708/publications.pdf>

Version: 2024-02-01

108
papers

916
citations

623188

14
h-index

713013

21
g-index

111
all docs

111
docs citations

111
times ranked

1197
citing authors

#	ARTICLE	IF	CITATIONS
1	Radical D2 gastrectomy with adjuvant chemotherapy for stage IB/II/III distal gastric cancers in the era of perioperative chemotherapy: A propensity matched comparison. American Journal of Surgery, 2022, 223, 1055-1062.	0.9	5
2	Red Cell Distribution Width and Gallbladder Cancer: Is It Really Useful?. Journal of Gastrointestinal Cancer, 2022, 53, 995-1005.	0.6	1
3	Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH). Oncologist, 2022, 27, 165-e222.	1.9	12
4	Learning curve analysis for lateral pelvic lymph node dissection in rectal cancers – Outcomes improve with experience. European Journal of Surgical Oncology, 2022, 48, 1110-1116.	0.5	10
5	Radiotherapy for locally advanced unresectable gallbladder cancer - A way forward. Journal of Cancer Research and Therapeutics, 2022, 18, 147-151.	0.3	2
6	Development of a New Tool to Assess the Quality of Life of Patients with Hand – Foot Syndrome Receiving Capecitabine-Based Therapy: A Pilot Study. South Asian Journal of Cancer, 2022, 11, 019-023.	0.2	1
7	Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant ¹⁸F¹⁸FDG Uptake. Neuroendocrinology, 2021, 111, 998-1004.	1.2	19
8	Addition of short course radiotherapy in newly diagnosed locally advanced rectal cancers with distant metastasis. Asia-Pacific Journal of Clinical Oncology, 2021, 17, e70-e76.	0.7	4
9	Curative resection for adenocarcinoma of the gastro-esophageal junction following neo-adjuvant chemotherapy – thoraco-abdominal vs. trans-abdominal approach. Langenbeck's Archives of Surgery, 2021, 406, 613-621.	0.8	2
10	Impact of Lumen Occlusion on Outcomes in Locally Advanced Rectal Adenocarcinoma. Indian Journal of Surgery, 2021, 83, 1401-1406.	0.2	0
11	Revision Surgery for Incidental Gallbladder Cancer – Challenging the Dogma: Ideal Timing and Real-World Applicability. Annals of Surgical Oncology, 2021, 28, 6758-6766.	0.7	14
12	Long-term oncological outcomes of the sphincter preserving total mesorectal excision with varying distal resection margins. Journal of Surgical Oncology, 2021, 123, 1784-1791.	0.8	3
13	Outcomes of exenteration in cT4 and fixed cT3 stage primary rectal adenocarcinoma: a subgroup analysis of consolidation chemotherapy following neoadjuvant concurrent chemoradiotherapy. Langenbeck's Archives of Surgery, 2021, 406, 821-831.	0.8	4
14	Efficacy of Capecitabine Plus Irinotecan vs Irinotecan Monotherapy as Second-line Treatment in Patients With Advanced Gallbladder Cancer. JAMA Oncology, 2021, 7, 436.	3.4	16
15	Cancer Aging Research Group (CARG) score in older adults undergoing curative intent chemotherapy: a prospective cohort study. BMJ Open, 2021, 11, e047376.	0.8	21
16	Towards standardization of management of gallbladder carcinoma with obstructive jaundice: Analysis of 113 cases over 10 years at a single institution. Journal of Surgical Oncology, 2021, 124, 572-580.	0.8	7
17	Pathological N3 Stage (pN3/ypN3) Gastric Cancer: Outcomes, Prognostic Factors and Pattern of Recurrences After Curative Treatment. Annals of Surgical Oncology, 2021, , 1.	0.7	6
18	ASO Visual Abstract: Pathologic N3 Stage (pN3/ypN3) Gastric Cancer – Outcomes, Prognostic Factors, and Pattern of Recurrences after Curative Treatment. Annals of Surgical Oncology, 2021, 28, 587.	0.7	0

#	ARTICLE	IF	CITATIONS
19	Optimal neoadjuvant strategy for signet ring cell carcinoma of the rectumâ€”Is TNT the solution?. Journal of Surgical Oncology, 2021, 124, 1417-1430.	0.8	14
20	MRI features of signet ring rectal cancer. Abdominal Radiology, 2021, 46, 5536-5549.	1.0	3
21	Laparoscopic versus open resection in locally advanced rectal cancers: a propensity matched analysis of oncological and shortâ€”term outcomes. Colorectal Disease, 2021, 23, 2894-2903.	0.7	3
22	Watch and Wait Approach After Neoadjuvant Chemoradiotherapy in Rectal Cancer: Initial Experience in the Indian subcontinent. Indian Journal of Surgical Oncology, 2021, 12, 664-670.	0.3	5
23	Prognostic value of lung shunt fraction in hepatocellular carcinoma and unresectable liver dominant metastatic colorectal cancer undergoing transarterial radioembolisation. Nuclear Medicine Communications, 2021, Publish Ahead of Print, 24-31.	0.5	1
24	Outcomes of Radical Surgical Resections for Nonâ€”metastatic Anorectal Melanomas: Experience from a Tertiary Care Centre. Colorectal Disease, 2021, , .	0.7	0
25	Prognostic value of imaging-based parameters in patients with intermediate-stage hepatocellular carcinoma undergoing transarterial radioembolization. Nuclear Medicine Communications, 2021, 42, 337-344.	0.5	3
26	Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas â€” are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?. Hpb, 2020, 22, 376-382.	0.1	9
27	Effect of a Structured Teaching Module Including Intensive Prophylactic Measures on Reducing the Incidence of Capecitabineâ€”Induced Handâ€”Foot Syndrome: Results of a Prospective Randomized Phase III Study. Oncologist, 2020, 25, e1886-e1892.	1.9	1
28	COVIDâ€”19 in cancer patients on active systemic therapy â€” Outcomes from LMIC scenario with an emphasis on need for active treatment. Cancer Medicine, 2020, 9, 8747-8753.	1.3	29
29	Impact of delaying surgery after chemoradiation in rectal cancer: outcomes from a tertiary cancer centre in India. Journal of Gastrointestinal Oncology, 2020, 11, 13-22.	0.6	6
30	Real-World Long-Term Outcomes with Perioperative EOX in D2 Gastrectomy: a Meaningful Look While We Switch to FLOT-4. Journal of Gastrointestinal Cancer, 2020, 51, 703-708.	0.6	2
31	Expert Consensus on Effective Management of Chemotherapy-Induced Nausea and Vomiting: An Indian Perspective. Frontiers in Oncology, 2020, 10, 400.	1.3	7
32	Initial experience of a geriatric oncology clinic in a tertiary cancer center in India. Cancer Research Statistics and Treatment, 2020, 3, 208.	0.1	22
33	Shared decision-making and medicolegal aspects: Delivering high-quality cancer care in India. Indian Journal of Palliative Care, 2020, 26, 405.	1.0	6
34	Gastrointestinal Stromal Tumor â€” An Overview. Indian Journal of Medical and Paediatric Oncology, 2020, 41, 809-818.	0.1	1
35	Presentation and Outcomes with First-Line Chemotherapy in Advanced Cholangiocarcinomasâ€”A Relatively Rare Component of Biliary Tract Cancers in India. South Asian Journal of Cancer, 2020, 09, 209-212.	0.2	2
36	Chemotherapy-Induced Nausea and Vomiting in Gastrointestinal Cancer Patients: Do We Need to Revisit Guidelines?. South Asian Journal of Cancer, 2020, 09, 245-249.	0.2	1

#	ARTICLE	IF	CITATIONS
37	Do Acellular Mucin Pools in Resection Margins for Rectal Cancer Influence Outcomes?. Indian Journal of Surgical Oncology, 2019, 10, 515-519.	0.3	3
38	Stereotactic body radio therapy for inoperable large hepatocellular cancers: results from a clinical audit. British Journal of Radiology, 2019, 92, 20181053.	1.0	12
39	A phase III randomised clinical trial of perioperative therapy (neoadjuvant chemotherapy versus) Tj ETQq1 1 0.784314 rgBT /Overlock 2019, 9, e028147.	0.8	14
40	Can CRM Status on MRI Predict Survival in Rectal Cancers: Experience from the Indian Subcontinent. Indian Journal of Surgical Oncology, 2019, 10, 364-371.	0.3	4
41	Role of Adjuvant Chemotherapy in Resected T2N0 Gall Bladder Cancer. Journal of Gastrointestinal Surgery, 2019, 23, 2232-2238.	0.9	6
42	Robotic versus laparoscopic sphincterâ€preserving total mesorectal excision: A propensity caseâ€matched analysis. International Journal of Medical Robotics and Computer Assisted Surgery, 2019, 15, e1965.	1.2	13
43	Neuroendocrine Carcinoma of Gallbladder: A Step Beyond Palliative Therapy, Experience of 25 Cases. Journal of Gastrointestinal Cancer, 2019, 50, 298-303.	0.6	18
44	Core Set of Patient-reported Outcomes in Pancreatic Cancer (COPRAC). Annals of Surgery, 2019, 270, 158-164.	2.1	44
45	Management of colon cancer at a tertiary referral center in India - Patterns of presentation, treatment, and survival outcomes. Indian Journal of Cancer, 2019, 56, 297.	0.2	6
46	Peptide Receptor Radionuclide Therapy in the Management of Neuroendocrine Tumors (Neoplasms): Fundamentals and Salient Clinical Practice Points for Medical Oncologists. Indian Journal of Medical and Paediatric Oncology, 2019, 40, 165-171.	0.1	5
47	Systemic chemotherapy and short-course radiation in metastatic rectal cancers: A feasible paradigm in unresectable and potentially resectable cancers. South Asian Journal of Cancer, 2019, 08, 092-097.	0.2	2
48	Pazopanib use preceding curative surgery in low rectal gastrointestinal stromal tumors after imatinib failure: A case report. South Asian Journal of Cancer, 2019, 08, 51-64.	0.2	1
49	Practice patterns and outcomes with the use of regorafenib in metastatic colorectal cancer: Results from the Regorafenib in Metastatic colorectal cancer - An Indian exploratory analysis study. South Asian Journal of Cancer, 2019, 08, 22-26.	0.2	2
50	Calculation of a clinical predictive factors identifying peritoneal disease on a staging laparoscopy in gastric cancers. South Asian Journal of Cancer, 2019, 08, 166-167.	0.2	3
51	Adjuvant chemotherapy in stage IIâ€III operated colon cancer patients from a nontrial cohort in a low colon cancer prevalence country with predominant use of modified CAPOX. South Asian Journal of Cancer, 2019, 08, 160-165.	0.2	0
52	Does histology dictate outcomes of locally advanced rectal adenocarcinoma with complete pathological response following neoadjuvant chemoradiation?. Journal of Radiation Oncology, 2018, 7, 85-89.	0.7	1
53	Outcome of neoadjuvant chemotherapy in â€œlocally advanced/borderline resectableâ€gallbladder cancer: the need to define indications. Hpb, 2018, 20, 841-847.	0.1	50
54	Gemcitabineâ€cisplatin (GC) as adjuvant chemotherapy in resected stage II and stage III gallbladder cancers (GBC): a potential way forward. Medical Oncology, 2018, 35, 57.	1.2	7

#	ARTICLE	IF	CITATIONS
55	Emerging role of multimodality treatment in gall bladder cancer: Outcomes following 510 consecutive resections in a tertiary referral center. <i>Journal of Surgical Oncology</i> , 2018, 117, 372-379.	0.8	29
56	Low prevalence of deficient mismatch repair (dMMR) protein in locally advanced rectal cancers (LARC) and treatment outcomes. <i>Journal of Gastrointestinal Oncology</i> , 2018, 10, 19-29.	0.6	12
57	Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 845-855.	3.7	32
58	Impact of histological subtype on treatment outcomes in locally advanced rectal adenocarcinoma treated with neoadjuvant chemoradiation. <i>Acta Oncologica</i> , 2018, 57, 1721-1723.	0.8	11
59	Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors. <i>Nuclear Medicine Communications</i> , 2018, 39, 1143-1149.	0.5	14
60	Pulmonary metastasectomy of colorectal cancer origin: Evaluating process and outcomes. <i>Journal of Surgical Oncology</i> , 2018, 118, 1292-1300.	0.8	5
61	Resection of Isolated Port Site Metastasis in Gall Bladder Cancers—Careful Selection and Perioperative Systemic Therapy May Improve Outcomes. <i>Indian Journal of Surgical Oncology</i> , 2018, 9, 427-431.	0.3	4
62	Docetaxel/Oxaliplatin/Capecitabine (TEX) triplet followed by continuation monotherapy in advanced gastric cancer. <i>Indian Journal of Cancer</i> , 2018, 55, 88.	0.2	3
63	Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?. <i>Indian Journal of Cancer</i> , 2018, 55, 138.	0.2	5
64	An evaluation of early-onset fatigue and the related coping strategies in patients with gastrointestinal cancer: A prospective pilot study. <i>Indian Journal of Cancer</i> , 2018, 55, 162.	0.2	3
65	Experience with non-cremophor-based paclitaxel-gemcitabine regimen in advanced pancreatic cancer: Results from a single tertiary cancer centre. <i>Indian Journal of Medical Research</i> , 2018, 148, 284.	0.4	5
66	Modified 5-fluorouracil/leucovorin/irinotecan as a feasible and efficacious second-line chemotherapeutic regimen in advanced gastric cancers. <i>South Asian Journal of Cancer</i> , 2018, 07, 219-222.	0.2	2
67	Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in India. <i>Indian Journal of Cancer</i> , 2018, 55, 144.	0.2	2
68	Chicken pox infection in patients undergoing chemotherapy: A retrospective analysis from a tertiary care center in India. <i>Journal of Infection and Public Health</i> , 2017, 10, 8-13.	1.9	4
69	Gemcitabine-cisplatin versus gemcitabine-oxaliplatin doublet chemotherapy in advanced gallbladder cancers: a match pair analysis. <i>Journal of Hepato-Biliary-Pancreatic Sciences</i> , 2017, 24, 262-267.	1.4	14
70	Additional chemotherapy and salvage surgery for poor response to chemoradiotherapy in rectal cancers. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, 322-328.	0.7	5
71	Role of adjuvant chemotherapy in T2N0M0 periampullary cancers. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2017, 13, e298-e303.	0.7	3
72	Ovarian Metastases of Colorectal Origin: Treatment Patterns and Factors Affecting Outcomes. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 519-526.	0.3	14

#	ARTICLE	IF	CITATIONS
73	Laparoscopic Versus Open Approach for Intersphincteric Resectionâ€”Results from a Tertiary Cancer Center in India. <i>Indian Journal of Surgical Oncology</i> , 2017, 8, 474-478.	0.3	3
74	Peritoneal Carcinomatosis in Colorectal Cancers â€” Management Perspective Needs a Change. <i>Clinical Colorectal Cancer</i> , 2017, 16, e1-e6.	1.0	5
75	A Case of Ruptured Adult Embryonal Sarcoma of the Liver with Excellent Outcome After Neoadjuvant Chemotherapy. <i>Journal of Gastrointestinal Cancer</i> , 2017, 48, 100-102.	0.6	4
76	Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. <i>Journal of Gastric Cancer</i> , 2017, 17, 21.	0.9	10
77	Treatment of advanced Gall bladder cancer in the real worldâ€”can continuation chemotherapy improve outcomes?. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 368-376.	0.6	9
78	What drives the wheel towards long-term outcome in advanced GIST, its size, genotype or may be a pill or two of imatinib?. <i>Translational Gastroenterology and Hepatology</i> , 2017, 2, 94-94.	1.5	1
79	Early outcomes of exon 11 mutants in GIST treated with standard dose Imatinib. <i>Annals of Translational Medicine</i> , 2017, 5, 134-134.	0.7	11
80	EMERALD: Emergency visit audit of patients treated under medical oncology in a tertiary cancer center: Logical steps to decrease the burden. <i>South Asian Journal of Cancer</i> , 2017, 06, 186-189.	0.2	4
81	Unraveling the spectrum of KIT mutations in gastrointestinal stromal tumors: An Indian Tertiary Cancer Center Experience. <i>South Asian Journal of Cancer</i> , 2017, 06, 113-117.	0.2	9
82	Clinical practice and outcomes in advanced gastrointestinal stromal tumor: Experience from an Indian tertiary care center. <i>South Asian Journal of Cancer</i> , 2017, 06, 110-112.	0.2	5
83	Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon. <i>Indian Journal of Cancer</i> , 2017, 54, 530.	0.2	3
84	Early outcomes of radiofrequency ablation in unresectable metastatic colorectal cancer from a tertiary cancer hospital in India. <i>Indian Journal of Radiology and Imaging</i> , 2017, 27, 200-206.	0.3	3
85	Surgical outcomes of post chemoradiotherapy unresectable locally advanced rectal cancers improve with interim chemotherapy, is FOLFIRINOX better than CAPOX?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 958-967.	0.6	10
86	Multivisceral resections for rectal cancers: short-term oncological and clinical outcomes from a tertiary-care center in India. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 345-353.	0.6	3
87	Dihydro pyrimidine dehydrogenase deficiency in patients treated with capecitabine based regimens: a tertiary care centre experience. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 380-386.	0.6	13
88	Pazopanib in metastatic multiply treated progressive gastrointestinal stromal tumors: feasible and efficacious. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 638-643.	0.6	8
89	Restaging after neoadjuvant chemoradiation in rectal cancers: is histology the key in patient selection?. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 360-364.	0.6	5
90	Neoadjuvant imatinib: longer the better, need to modify risk stratification for adjuvant imatinib. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 624-631.	0.6	12

#	ARTICLE	IF	CITATIONS
91	Observation on enhanced avidity on somatostatin receptor targeted 68Ga-DOTATATE PET-CT following therapy with everolimus and capecitabineâ€”temozolamide. Nuclear Medicine Communications, 2016, 37, 669-671.	0.5	12
92	PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors. PET Clinics, 2016, 11, 233-241.	1.5	7
93	The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2453-2455.	3.3	9
94	Rectal GISTâ€™Outcomes and viewpoint from a tertiary cancer center. Indian Journal of Gastroenterology, 2016, 35, 445-449.	0.7	7
95	Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor. Nuclear Medicine Communications, 2016, 37, 1030-1037.	0.5	39
96	Second-Line Palliative Chemotherapy in Advanced Gall Bladder Cancer, CAP-IRI: Safe and Effective Option. Journal of Gastrointestinal Cancer, 2016, 47, 305-312.	0.6	14
97	Neoadjuvant Imatinib in Locally Advanced Gastrointestinal stromal Tumours, Will Kit Mutation Analysis Be a Pathfinder?. Journal of Gastrointestinal Cancer, 2016, 47, 381-388.	0.6	5
98	Self-identification and management of hand-foot syndrome (HFS): effect of a structured teaching program on patients receiving capecitabine-based chemotherapy for colon cancer. Supportive Care in Cancer, 2016, 24, 2575-2581.	1.0	16
99	Oxaliplatin-related neuropathy in Indian patients â€” no difference between generic and original molecules. Indian Journal of Medical and Paediatric Oncology, 2016, 37, 271-277.	0.1	2
100	Signet ring colorectal carcinoma: Do we need to improve the treatment algorithm?. World Journal of Gastrointestinal Oncology, 2016, 8, 819.	0.8	15
101	Impact of type of surgery (laparoscopic versus open) on the time to initiation of adjuvant chemotherapy in operable rectal cancers. Indian Journal of Gastroenterology, 2015, 34, 310-313.	0.7	2
102	Supportive Measures and Finer Practice Points in 177Lu-DOTATATE PRRT for NET: Aiming for Optimal Disease Management. Journal of Nuclear Medicine, 2014, 55, 1916-1917.	2.8	5
103	Role of paclitaxel and platinum-based adjuvant chemotherapy in high-risk penile cancer. Urology Annals, 2012, 4, 150.	0.3	39
104	Primitive Neuroectodermal Tumor of Ovary in a Young Lady, Confirmed with Molecular and Cytogenetic Resultsâ€™A Rare Case Report with a Diagnostic and Therapeutic Challenge. Pathology and Oncology Research, 2012, 18, 1101-1106.	0.9	14
105	Lead intoxication mimicking a malignancy. Hematology/ Oncology and Stem Cell Therapy, 2011, 4, 146-147.	0.6	3
106	Type B insulin resistance in a systemic lupus erythematosus patient. International Journal of Rheumatic Diseases, 2009, 12, 174-176.	0.9	8
107	An Analysis of Tolerance and Early Survival Outcomes with Perioperative Modified FLOT in Gastric Cancers. South Asian Journal of Cancer, 0, , .	0.2	1
108	The Prevalence of BRAF, PIK3CA, and RAS Mutations in Indian Patients with Colorectal Cancer. South Asian Journal of Cancer, 0, , .	0.2	0